Obesity Drug Markets in the US and EU: Analysis of product pipelines and the competitive environmen

Table of Contents

Executive Summary

• The large and growing obesity problem
• Current approaches to obesity management
• Pharmaceutical options for the treatment of obesity
• The obesity drug pipeline
• Market forecasts

Chapter 1 The large and growing obesity problem

• Summary
• A potentially life threatening medical condition
• Levels of obesity
• Overweight
• Obesity
• Morbid obesity
• Super obesity
• Co-morbidities and mortality
  • Arthritis
  • Asthma
  • Cancer
  • Cardiovascular disease and hypertension
  • Dementia
  • Depression
  • Diabetes
  • Kidney disease
• Rising prevalence of obesity
• Trends by sub-population
  • United States
  • Europe
• Obesity in children and adolescents
• Heavy social and economic impact
• Cost burden
• Social effects
• Societal and other effects
• Medical overview of obesity
• Pathogenesis of obesity
• Physiological factors
• Genetic factors
• Environmental factors
• Lifestyle factors
• Psychological factors
• Societal trends
• Obesity as a component of metabolic syndrome
• Conclusion

Chapter 2 Current approaches to obesity management

• Summary
• Background
• Diet and exercise programs
• Dieting
  • Types of programs
  • Patient volumes
• Exercise
  • Types of programs
  • Patient volumes
• OTC weight loss supplements
  • Types of products
  • Patient volumes
• Pharmaceutical options
  • Types of medications
  • Patient volumes
• Surgical intervention
  • Types of procedures
  • Patient volumes
• Comparison of options
• Safety
• Efficacy
• Cost
  • Insurance reimbursement
• Unmet needs
• Conclusion

Chapter 3 Pharmaceutical options for treatment of obesity

• Summary
• Leading prescription medications
• Meridia
• Xenical
• Acomplia
• Others
• OTC medicines
• Alli
• Comparison of pharmaceutical options
• Safety
• Efficacy
• Cost
  • Insurance reimbursement
• Conclusion

Chapter 4 The obesity drug pipeline

• Summary
• Introduction
• Pre-clinical testing
• Phase I testing
• Phase II testing
• Phase III testing
• Leading obesity drug candidates
• Lorcaserin hydrochloride
• Lepislim
• Taranabant
• Contrave
• CP-945,598
• Qnexa
• Discontinued obesity drug candidates
• Conclusion

Chapter 5 Market forecasts

• Summary
• Introduction
• Current sales levels
• United States
• Europe
• Five year forecasts
• United States
• Europe
• Conclusion
• Index

List of Figures

• Figure 1.1: Rates of obesity and overweight in the US, 1980-2006
• Figure 1.2: Rates of obesity and overweight in Europe, 1980-2006
• Figure 2.3: Comparison of safety, efficacy and cost of obesity management approaches
• Figure 3.4: Comparison of safety, efficacy and cost of pharmaceutical options for obesity management
• Figure 4.5: Comparison of leading obesity drug candidates, 2008
• Figure 5.6: Obesity medication sales in the US and EU, 2006 and 2007
• Figure 5.7: Obesity medication sales by region, 2007
• Figure 5.8: Obesity medication sales in the US and EU, 2008-2013
• Figure 5.9: Total obesity medication sales by region, 2008-2013

List of Tables

• Table 1.1: Proportion of cancers related to obesity
• Table 1.2: Prevalence of adult overweight and obesity by country, 2003
• Table 2.3: US and EU patient caseloads for leading obesity management approaches, 2007-12 (millions of persons)
• Table 2.4: Safety risks associated with obesity management approaches
• Table 2.5: Comparative efficacy of obesity management approaches
• Table 3.6: Safety risks associated with leading obesity medications
• Table 3.7: Safety risks associated with leading obesity management approaches
• Table 3.8: US cost comparison for leading obesity medications, 2008
• Table 4.9: Pharmaceutical pipeline for obesity medications
• Table 4.10: Discontinuations of obesity drug programs
• Table 5.11: US sales of obesity medications, 2006 and 2007
• Table 5.12: European sales of obesity medications, 2006 and 2007
• Table 5.13: US sales of obesity medications in $m, 2008-2012
• Table 5.14: European sales of obesity medications in $m, 2008-2012